PolyPid Ltd
PYPD3.460USD
+0.050+1.47%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
35.26MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über PolyPid Ltd Unternehmen
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Unternehmensinformationen
BörsenkürzelPYPD
Name des UnternehmensPolyPid Ltd
IPO-datumJun 26, 2020
CEOMs. Dikla Czaczkes Akselbrad
Anzahl der mitarbeiter57
WertpapierartOrdinary Share
GeschäftsjahresendeJun 26
Addresse18 Hasivim Street, P.O Box 7126
StadtPETAH TIKVA
BörseNASDAQ Capital Market Consolidated
LandIsrael
Postleitzahl4917002
Telefon972747195700
Websitehttps://www.polypid.com
BörsenkürzelPYPD
IPO-datumJun 26, 2020
CEOMs. Dikla Czaczkes Akselbrad
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Yechezkel Barenholz, Ph.D.
Dr. Yechezkel Barenholz, Ph.D.
Independent Director
Independent Director
2.76K
--
Ms. Dikla Czaczkes Akselbrad
Ms. Dikla Czaczkes Akselbrad
Chief Executive Officer, Director
Chief Executive Officer, Director
934.00
+100.00%
Dr. Itzhak Krinsky, Ph.D.
Dr. Itzhak Krinsky, Ph.D.
Independent Director
Independent Director
833.00
--
Mr. Jacob Harel
Mr. Jacob Harel
Independent Chairman of the Board
Independent Chairman of the Board
467.00
--
Mr. Ori Warshavsky
Mr. Ori Warshavsky
Chief Operating Officer - US
Chief Operating Officer - US
267.00
--
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
--
--
Dr. Shaul Mukhtar, Ph.D.
Dr. Shaul Mukhtar, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Ms. Dalit Hazan
Ms. Dalit Hazan
Senior Vice President - Research and Development and Regulatory Affairs
Senior Vice President - Research and Development and Regulatory Affairs
--
--
Dr. Noam Emanuel, Ph.D.
Dr. Noam Emanuel, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Robert Burton (Bob) Stein, M.D., Ph.D.
Dr. Robert Burton (Bob) Stein, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Yechezkel Barenholz, Ph.D.
Dr. Yechezkel Barenholz, Ph.D.
Independent Director
Independent Director
2.76K
--
Ms. Dikla Czaczkes Akselbrad
Ms. Dikla Czaczkes Akselbrad
Chief Executive Officer, Director
Chief Executive Officer, Director
934.00
+100.00%
Dr. Itzhak Krinsky, Ph.D.
Dr. Itzhak Krinsky, Ph.D.
Independent Director
Independent Director
833.00
--
Mr. Jacob Harel
Mr. Jacob Harel
Independent Chairman of the Board
Independent Chairman of the Board
467.00
--
Mr. Ori Warshavsky
Mr. Ori Warshavsky
Chief Operating Officer - US
Chief Operating Officer - US
267.00
--
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Aurum Ventures M.K.I.
19.88%
Centaurus Investments Limited
10.87%
Rosalind Advisors, Inc.
9.99%
Nir (Yehuda)
6.02%
Hewlett Fund, L.P.
5.77%
Other
47.47%
Aktionäre
Aktionäre
Anteil
Aurum Ventures M.K.I.
19.88%
Centaurus Investments Limited
10.87%
Rosalind Advisors, Inc.
9.99%
Nir (Yehuda)
6.02%
Hewlett Fund, L.P.
5.77%
Other
47.47%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
19.88%
Hedge Fund
19.57%
Holding Company
10.87%
Individual Investor
9.02%
Corporation
5.77%
Investment Advisor/Hedge Fund
4.75%
Private Equity
4.54%
Investment Advisor
0.28%
Research Firm
0.02%
Other
25.31%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
41
7.61M
74.69%
+1.40M
2025Q1
42
7.66M
75.16%
+942.60K
2024Q4
44
5.48M
65.20%
+1.87M
2024Q3
50
4.47M
69.98%
+1.49M
2024Q2
58
3.43M
73.51%
+1.59M
2024Q1
59
3.33M
71.29%
+2.56M
2023Q4
54
443.78K
34.10%
+80.67K
2023Q3
57
479.04K
37.01%
+97.48K
2023Q2
57
472.86K
36.65%
+91.51K
2023Q1
59
332.36K
28.62%
+89.40K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Aurum Ventures M.K.I.
2.03M
19.88%
+11.34K
+0.56%
Feb 26, 2025
Centaurus Investments Limited
1.11M
10.87%
+475.10K
+75.12%
Dec 31, 2024
Rosalind Advisors, Inc.
1.02M
9.99%
--
--
Mar 31, 2025
Nir (Yehuda)
613.91K
6.02%
+62.60K
+11.36%
Mar 31, 2025
Hewlett Fund, L.P.
587.92K
5.77%
+338.44K
+135.66%
Feb 26, 2025
Triple Gate Capital, LP
465.84K
4.57%
+465.84K
--
Feb 26, 2025
AIGH Capital Management, LLC.
510.95K
5.01%
-507.07K
-49.81%
Mar 31, 2025
Worth Venture Partners, LLC
429.43K
4.21%
+153.81K
+55.80%
Mar 31, 2025
Lukach (Aharon)
299.55K
2.94%
-5.64K
-1.85%
Mar 31, 2025
Dafna Capital Management, LLC
291.27K
2.86%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
Datum
Art
Verhältnis
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
